India News | Alembic Pharma Gets Final USFDA Nod for Generic Version of Arformoterol Tartrate Inhalation Solution

New Delhi, May 11 (PTI) Alembic Pharmaceuticals Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.

The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial, the company said in a statement.

Also Read | Apple iPod Discontinued After 20 Years, iPod Touch Model To Be Available While Supplies Last.

The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD), Brovana inhalation solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc, it added.

Arformoterol Tartrate inhalation solution is indicated for long-term, twice daily administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the company said.

Also Read | Delhi Shocker: 14-Year-Old Girl Raped, Forced to Undergo Abortion; 4 Arrested.

This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies Pvt Ltd, it added.

Citing IQVIA data, the company said Arformoterol Tartrate inhalation solution, 15 mcg (base)/2 mL unit-dose vial, had an estimated market size of USD 251 million for the 12 months ended December 2021.

Alembic said it has a cumulative total of 167 ANDA approvals (143 final approvals and 24 tentative approvals) from USFDA, including this second inhalational ANDA approval.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)